Exencial Wealth Advisors LLC Sells 464 Shares of Danaher Co. (NYSE:DHR)

Exencial Wealth Advisors LLC cut its stake in shares of Danaher Co. (NYSE:DHR) by 3.7% during the 4th quarter, HoldingsChannel reports. The firm owned 12,049 shares of the conglomerate’s stock after selling 464 shares during the period. Exencial Wealth Advisors LLC’s holdings in Danaher were worth $2,766,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in DHR. Heck Capital Advisors LLC bought a new stake in shares of Danaher during the 4th quarter valued at approximately $27,000. Decker Retirement Planning Inc. bought a new stake in shares of Danaher during the 4th quarter valued at approximately $31,000. Golden State Wealth Management LLC bought a new stake in shares of Danaher during the 4th quarter valued at approximately $31,000. Strategic Financial Concepts LLC bought a new stake in shares of Danaher during the 4th quarter valued at approximately $31,000. Finally, Pineridge Advisors LLC grew its holdings in shares of Danaher by 63.3% during the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 57 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Up 0.1 %

Danaher stock opened at $205.92 on Wednesday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The firm’s fifty day moving average is $223.61 and its 200 day moving average is $243.86. The company has a market capitalization of $147.17 billion, a PE ratio of 39.00, a PEG ratio of 2.66 and a beta of 0.82.

Danaher (NYSE:DHR) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the firm posted $2.09 EPS. As a group, sell-side analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 annualized dividend and a yield of 0.62%. Danaher’s dividend payout ratio is presently 24.24%.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of a number of research reports. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a report on Friday, December 13th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Citigroup reduced their target price on shares of Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Barclays reduced their target price on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Finally, Robert W. Baird reduced their target price on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Seven analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.